Niversity of Oregon, Portland, OR; Steven H.B. Han, M.D., University of California, Los Angeles, CA; Robert Fontana, M.D., University of Michigan, Ann Arbor, MI; Brendan McGuire, M.D., University of Alabama, Birmingham, AL; Ray Chung, M.D., Massachusetts General Hospital, Boston, MA; Alastair Smith, MB, ChB, Duke University Medical Center, Durham, NC; Robert Brown, M.D., Cornell/Columbia University, NY, NY; Jeffrey Crippin, M.D., Washington University, St. Louis, MO; Edwin Harrison, Mayo Clinic, Scottsdale, AZ; Adrian Reuben, MBBS, Healthcare University of South Carolina, Charleston, SC; Santiago Munoz, M.D., Albert Einstein Health-related Center, Philadelphia, PA; Rajender Reddy, M.D., University of Pennsylvania, Philadelphia, PA; R. Todd Stravitz, M.D., Virginia Commonwealth University, Richmond, VA; Lorenzo Rossaro, M.D., University of California Davis, Sacramento, CA; Raj Satyanarayana, M.D., Mayo Clinic, Jacksonville, FL; and Tarek Hassanein, M.D., University of California, San Diego, CA. The University of Texas Southwestern Administrative Group included Grace Samuel, Ezmina Lalani, Carla Pezzia, and Corron Sanders, Ph.D., and also the Statistics and Data Management Group included Joan Reisch, Ph.D., Linda Hynan, Ph.D., Janet P. Smith, Joe W.957135-12-5 Purity Webster, and Mechelle Murry. We additional acknowledge each of the coordinators in the study sites who participated in this study.Formula of N-Fmoc-2,5-difluoro-L-phenylalanine Hepatology.PMID:24406011 Author manuscript; available in PMC 2014 April 20.Reuben et al. Supported by the National Institutes of Health (NIH) grant U-01-DK58369 (to W.M.L.).PageAbbreviationsALF ALT ANA BMI CAM CI DILI FDA INR IQR MELD NAC NSAID OR SD TMP-S UTSW acute liver failurey alanine aminotransferase antinuclear antibody physique mass index complementary and option medication self-confidence interval drug-induced liver injury U.S. Federal Drug Administration international normalized ratio interquartile range Model for End-Stage Liver Disease N-acetylcysteine nonsteroidal anti-inflammatory drug odds ratio normal deviation trimethoprimsulfamethoxazole University of Texas, SouthwesternNIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript
Neuro-Oncology 15(9):1160?1172, 2013. doi:ten.1093/neuonc/not067 Advance Access publication June 4,N E U RO – O N CO LO GYSynergy among the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomasShuo Xu, Qian-Qian Shao, Jin-Tang Sun, Ning Yang, Qi Xie, Dong-Hai Wang, Qi-Bing Huang, Bin Huang, Xin-Yu Wang, Xin-Gang Li, and Xun QuDepartment of Neurosurgery (S.X., N.Y., D.-H.W., B.H., X.-Y.W., X.-G.L.); Institute of Simple Medical Sciences and Key Laboratory of Cardiovascular Proteomics of Shandong Province (Q.-Q.S., J.-T.S., Q.X., X.Q.); and Division of Emergency Surgery, Qilu Hospital of Shandong University, Jinan, China (Q.-B.H.); Brain Science Study Institute, Shandong University, Jinan, China (S.X., N.Y., D.-H.W., B.H., X.-Y.W., X.-G.L.)Background. The significance of ectoenzymes CD39 and CD73 in mediating adenosinergic immunosuppression has been recognized, but their roles in human malignant glioma ?related immunosuppression remain largely unknown. Methods. In this study, the ectoenzyme characteristics of malignant glioma cells and infiltrating CD4+ T lymphocytes isolated from newly diagnosed malignant glioma sufferers had been investigated. The ectoenzyme activities of each cell populations were determined by nucleotide hydrolysis assay. The immunosuppressive house in the CD39-CD73 synergic ef.